Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

About this funding opportunity

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Topic areas: Life Sciences and Health.

Funding amount

This grant provides Up to $300K in funding, up to $300K per award.

Deadline

Applications are due Nov 10, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Public Authorities
• Large Company
• University
• NGOs
• Other
• SME

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Agency

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) is administered by National Institutes of Health (NIH), listed via Grants.gov.